中晚期恶性肿瘤患者中药联合免疫检查点抑制剂治疗的疗效相关性探析  

An analysis on the curative effect of TCM medicine with immune checkpoint inhibitor on intermediate and advanced malignant tumor

作　　者：王冰冰 高宏[2] 李夏平[2] WANG Bingbing

机构地区：[1]辽宁中医药大学,辽宁沈阳110847 [2]辽宁中医药大学附属医院,辽宁沈阳110032

出　　处：《中医临床研究》2023年第14期50-56,共7页Clinical Journal Of Chinese Medicine

摘　　要：目的:研究中药联合免疫检查点抑制剂(Immune Checkpoint Inhibitors,ICI)治疗中晚期恶性肿瘤能否产生更佳的效果。方法:选取就诊于辽宁中医药大学附属医院肿瘤科住院部、初次使用ICI治疗的中晚期恶性肿瘤患者60名,根据是否使用中药分成两组,中药组和对照组。本研究纳入患者瘤种包括肺癌、肝癌、乳腺癌、食管癌、胰腺癌等共16种,其中以肺癌占比最大。统计两组患者的性别、年龄、瘤种、远处转移情况、ICI的使用情况、治疗线数、治疗方案、中医辨证分型及免疫部分缓解的时间并求出平均值,大于该平均值的记为1,小于的记为0;其余变量“是=1,否=0”。通过统计方法,对试验数据分别进行单因素分析、危险因素分析、正负反馈相关分析,且对其疗效预测价值使用受试者工作特征(Receiver Operating Characteristic,ROC)曲线进行分析。结果:中药组的免疫部分缓解时间更短(P<0.05),且对于免疫部分缓解时间呈负相关。中药组疗效预测价值的ROC曲线下面积(Area Under the Curve,AUC)值为0.699(P<0.05)。结论:中药联合ICI治疗中晚期恶性肿瘤的临床疗效呈正相关关系。Objective:To study To investigate whether TCM medicine plus immune checkpoint inhibitors can obtain better efficacy in the treatment of intermediate and advanced malignant tumor.Methods:Sixty patients with intermediate and advanced malignant tumors who were treated with immune checkpoint inhibitors for the first time in the Department of Oncology,Affiliated Hospital of Liaoning University of Traditional Chinese Medicine were selected and divided into two groups according to whether TCM was used.This study included 16 types of tumor species of patients,including lung cancer,liver cancer,breast cancer,esophageal cancer,and pancreatic cancer,of which lung cancer accounted for the largest proportion.The gender,age,tumor type,distant metastasis,use of immune checkpoint inhibitor,number of treatment lines,treatment regimen,TCM classification type and time of immune partial remission in the two groups were counted and the mean value was obtained.Those variates greater than the mean value were recorded as 1,and those less than the mean value were recorded as 0.The remaining variables were yes=1,no=0.Through statistical methods,the test data was treated for the single factor analysis,risk factor analysis,positive and negative feedback correlation analysis,and its efficacy prediction value was analyzed by ROC curve.Results:The duration of immune partial remission was shorter in the TCM group(P<0.05),and was negctively correlated with the immune partial remission time.The AUC value for the predictive value of efficacy in the TCM group was 0.699(P<0.05).Conclusion:The clinical efficacy of TCM medicine on malignant tumor was positively correlated with immune checkpoint inhibitor.

关 键 词：恶性肿瘤 免疫抑制剂 中医中药 免疫部分缓解时间 增效 

分 类 号：R273[医药卫生—中西医结合]